{"entity":{"id":"2009","kind":"year","name":"2009 in oncology","aka":["2009"],"tldr":"Everything OnCo dates to 2009: 190 entries, 49 landmarks, 49 papers listed on people's pages, 47 papers and 17 approvals. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"190 dated entries in OnCo fall in 2009: 49 landmarks, 49 papers listed on people's pages, 47 papers, 17 approvals, 13 trials reported, 5 companies founded, 4 journals founded, 4 technologies and 2 laws and regulations.\n\nOf those, 190 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["2008","2010"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":2009,"events":[{"group":"approval","date":"2009","precision":"year","title":"Bevacizumab (glioblastoma use) approved in US","note":"Recurrent glioblastoma (accelerated; full approval 2017)","from":"bevacizumab-glioma","refs":[]},{"group":"approval","date":"2009","precision":"year","title":"Catumaxomab approved in EU","note":"Malignant ascites in EpCAM-positive carcinomas when standard therapy is unavailable (Removab; withdrawn 2017)","from":"catumaxomab","refs":[]},{"group":"approval","date":"2009","precision":"year","title":"Degarelix approved in EU","note":"Same","from":"degarelix","refs":[]},{"group":"approval","date":"2009","precision":"year","title":"Epoetin theta approved in EU","note":"Symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy; anaemia of chronic renal failure.","from":"epoetin-theta","refs":[]},{"group":"approval","date":"2009","precision":"year","title":"Everolimus approved in US","note":"Advanced RCC after sunitinib or sorafenib","from":"everolimus","refs":[]},{"group":"approval","date":"2009","precision":"year","title":"Gefitinib approved in EU","note":"EGFR-mutant NSCLC","from":"gefitinib","refs":[]},{"group":"approval","date":"2009","precision":"year","title":"HPV bivalent vaccine (types 16 and 18) approved in US","note":"Prevention of cervical cancer and precursor lesions caused by HPV 16 and 18 in females 10 to 25 (discontinued in the US 2016)","from":"hpv-bivalent-vaccine","refs":[]},{"group":"approval","date":"2009","precision":"year","title":"Ibritumomab tiuxetan approved in US","note":"Consolidation after first-line chemotherapy in previously untreated follicular NHL","from":"ibritumomab-tiuxetan","refs":[]},{"group":"approval","date":"2009","precision":"year","title":"Mifamurtide approved in EU","note":"High-grade resectable non-metastatic osteosarcoma after complete resection, with chemotherapy, ages 2-30","from":"mifamurtide","refs":[]},{"group":"approval","date":"2009","precision":"year","title":"Ofatumumab approved in US","note":"CLL refractory to fludarabine and alemtuzumab (accelerated)","from":"ofatumumab","refs":[]},{"group":"approval","date":"2009","precision":"year","title":"Pazopanib approved in US","note":"Advanced renal cell carcinoma","from":"pazopanib","refs":[]},{"group":"approval","date":"2009","precision":"year","title":"Plerixafor approved in EU","note":"Stem cell mobilisation with G-CSF in lymphoma and multiple myeloma with poor mobilisation (Mozobil)","from":"plerixafor","refs":[]},{"group":"approval","date":"2009","precision":"year","title":"Pralatrexate approved in US","note":"Relapsed/refractory peripheral T-cell lymphoma","from":"pralatrexate","refs":[]},{"group":"approval","date":"2009","precision":"year","title":"Romidepsin approved in US","note":"Cutaneous T-cell lymphoma after ≥1 systemic therapy","from":"romidepsin","refs":[]},{"group":"approval","date":"2009","precision":"year","title":"Topotecan approved in England (NICE)","note":"Relapsed small-cell lung cancer, oral topotecan, only where re-treatment with the first-line regimen is inappropriate and cyclophosphamide, doxorubicin and vincristine is contraind...","from":"topotecan","refs":[]},{"group":"approval","date":"2009","precision":"year","title":"Trabectedin approved in EU","note":"Relapsed platinum-sensitive ovarian cancer with PLD","from":"trabectedin","refs":[]},{"group":"approval","date":"2009","precision":"year","title":"Vinflunine approved in EU","note":"Advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a platinum-containing regimen","from":"vinflunine","refs":[]},{"group":"company","date":"2009","precision":"year","title":"Andreessen Horowitz Bio + Health founded","note":"Menlo Park, CA","from":"a16z-bio-health","refs":[]},{"group":"company","date":"2009","precision":"year","title":"Atossa Therapeutics founded","note":"Seattle, WA","from":"atossa-therapeutics","refs":[]},{"group":"company","date":"2009","precision":"year","title":"ETOP IBCSG Partners Foundation founded","note":"Bern","from":"etop-ibcsg","refs":[]},{"group":"company","date":"2009","precision":"year","title":"GV (Google Ventures) founded","note":"Mountain View, CA","from":"gv","refs":[]},{"group":"company","date":"2009","precision":"year","title":"Suzhou Zelgen Biopharmaceuticals founded","note":"Suzhou","from":"zelgen","refs":[]},{"group":"history","date":"2009","precision":"year","title":"AALL0031: continuous imatinib with chemotherapy gives 80 percent three-year event-free survival","note":"Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)","from":"all-paediatric-ph-positive","refs":["imatinib"]},{"group":"history","date":"2009","precision":"year","title":"ACOSOG Z9001: one year of adjuvant imatinib reduces recurrence","note":"KIT exon 11-mutant GIST","from":"gist-kit-exon-11","refs":["imatinib"]},{"group":"history","date":"2009","precision":"year","title":"AZA-001: azacitidine lengthens survival in higher-risk MDS","note":"Higher-risk myelodysplastic syndromes","from":"mds-higher-risk","refs":["azacitidine"]},{"group":"history","date":"2009","precision":"year","title":"Bethesda System for thyroid cytology standardises nodule reporting","note":"Thyroid cancer","from":"thyroid","refs":["bethesda-category","thyroid-fna-molecular"]},{"group":"history","date":"2009","precision":"year","title":"Bevacizumab accelerated approval at recurrence","note":"Glioma & glioblastoma. Radiographic response without survival benefit.","from":"glioblastoma","refs":["bevacizumab-glioma"]},{"group":"history","date":"2009","precision":"year","title":"Bevacizumab shrinks NF2 vestibular schwannomas and improves hearing","note":"Vestibular schwannoma (acoustic neuroma). Plotkin and colleagues (NEJM).","from":"vestibular-schwannoma","refs":["bevacizumab"]},{"group":"history","date":"2009","precision":"year","title":"CAPOX phase 2 establishes oxaliplatin-fluoropyrimidine as first-line therapy","note":"Advanced and metastatic small bowel adenocarcinoma","from":"advanced-small-bowel-adenocarcinoma","refs":["capox"]},{"group":"history","date":"2009","precision":"year","title":"Charing Cross series identifies an interval of over four years as the strongest predictor of death","note":"Placental-site trophoblastic tumour and epithelioid trophoblastic tumour","from":"placental-site-trophoblastic-tumour","refs":[]},{"group":"history","date":"2009","precision":"year","title":"Conformal radiotherapy safe and effective in young children","note":"Ependymoma. St Jude RT1 (Merchant, Lancet Oncology) shows tumour-bed irradiation controls disease with preserved cognition.","from":"ependymoma","refs":["imrt-igrt"]},{"group":"history","date":"2009","precision":"year","title":"DICER1 germline mutations cause familial PPB","note":"Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours). Hill and colleagues (Science) identify the first microRNA-processing gene tumour syndrome.","from":"pleuropulmonary-blastoma","refs":[]},{"group":"history","date":"2009","precision":"year","title":"ENSAT staging","note":"Adrenocortical carcinoma","from":"adrenocortical","refs":[]},{"group":"history","date":"2009","precision":"year","title":"ENSAT staging system published","note":"Localised adrenocortical carcinoma (ENSAT stage I to III, resectable)","from":"localised-adrenocortical-carcinoma","refs":["staging-systems"]},{"group":"history","date":"2009","precision":"year","title":"EPCAM deletions as a cause of Lynch syndrome","note":"Colorectal cancer. Loss of the 3' exons of EPCAM silences the neighbouring MSH2 gene by transcriptional read-through, in EpCAM-expressing tissue only.","from":"colorectal","refs":["paper-ligtenberg-epcam-deletion-msh2-silencing-nat-genet-2009","epcam"]},{"group":"history","date":"2009","precision":"year","title":"Everolimus approved second line (RECORD-1)","note":"Renal cell carcinoma","from":"rcc","refs":["everolimus"]},{"group":"history","date":"2009","precision":"year","title":"First report of a metastatic medulloblastoma responding to a smoothened inhibitor","note":"SHH-activated medulloblastoma","from":"medulloblastoma-shh","refs":["vismodegib"]},{"group":"history","date":"2009","precision":"year","title":"FOXL2 C134W mutation found in almost all adult granulosa cell tumours","note":"Adult granulosa cell tumour of the ovary","from":"granulosa-cell-tumour","refs":[]},{"group":"history","date":"2009","precision":"year","title":"Germline TBXT duplication in familial chordoma","note":"Chordoma. Yang and colleagues (Nat Genet).","from":"chordoma","refs":[]},{"group":"history","date":"2009","precision":"year","title":"GNAQ mutations discovered (Van Raamsdonk); GNA11 in 2010","note":"Uveal melanoma","from":"uveal-melanoma","refs":[]},{"group":"history","date":"2009","precision":"year","title":"GOG-0204: cisplatin-paclitaxel confirmed as the reference doublet","note":"Recurrent or metastatic cervical cancer","from":"recurrent-metastatic-cervical-cancer","refs":["cisplatin","paclitaxel"]},{"group":"history","date":"2009","precision":"year","title":"Gronchi and Bonvalot report improved local control with extended en bloc resection","note":"Retroperitoneal sarcoma","from":"retroperitoneal-sarcoma","refs":[]},{"group":"history","date":"2009","precision":"year","title":"HPV vaccination shown to prevent external genital lesions in men","note":"Localised penile cancer (organ-confined, node-negative)","from":"localised-penile-cancer","refs":["hpv-vaccine","gardasil-9"]},{"group":"history","date":"2009","precision":"year","title":"IDH1 and IDH2 mutations define a glioma lineage","note":"Astrocytoma, IDH-mutant (grades 2 to 4). Yan and colleagues (NEJM) show IDH mutations in most grade 2 and 3 gliomas and their better prognosis.","from":"idh-mutant-astrocytoma","refs":["idh"]},{"group":"history","date":"2009","precision":"year","title":"IDH1 mutations found in AML after their discovery in glioma","note":"IDH1- and IDH2-mutated acute myeloid leukaemia","from":"aml-idh","refs":["idh"]},{"group":"history","date":"2009","precision":"year","title":"INRG classification defines the intermediate-risk group by stage, age and biology","note":"Intermediate-risk neuroblastoma","from":"neuroblastoma-intermediate-risk","refs":["inrg-staging"]},{"group":"history","date":"2009","precision":"year","title":"INRG classification unifies international risk grouping","note":"Neuroblastoma (paediatric)","from":"neuroblastoma","refs":["inrg-staging"]},{"group":"history","date":"2009","precision":"year","title":"International Neuroblastoma Risk Group classification published","note":"Low-risk neuroblastoma (INRG very low and low risk, including stage MS)","from":"neuroblastoma-low-risk","refs":["inrg-staging"]},{"group":"history","date":"2009","precision":"year","title":"IPASS: gefitinib beats chemotherapy in EGFR-mutant patients, worse in others; testing becomes mandatory","note":"EGFR-mutated non-small-cell lung cancer","from":"egfr-mutant-nsclc","refs":["gefitinib","tony-mok"]},{"group":"history","date":"2009","precision":"year","title":"IPASS: the biomarker, not the population","note":"Lung cancer (all types). 1,217 East Asian never-smokers and light former smokers randomised between gefitinib and chemotherapy; the benefit lived entirely in the EGFR-mutant subgro...","from":"lung-cancer","refs":["paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009","paper-lynch-egfr-activating-mutations-gefitinib-nejm-2004","paper-paez-egfr-mutations-gefitinib-science-2004"]},{"group":"history","date":"2009","precision":"year","title":"LAP2: laparoscopic hysterectomy equivalent to open surgery","note":"Endometrial cancer","from":"endometrial","refs":["robotic-surgery"]},{"group":"history","date":"2009","precision":"year","title":"Long-course beats short-course androgen deprivation with radiotherapy in high-risk disease","note":"Localised prostate cancer, high and very high risk","from":"prostate-high-risk","refs":["androgen-deprivation"]},{"group":"history","date":"2009","precision":"year","title":"MACH-NC update: concomitant chemotherapy adds about 6.5 points to five-year survival","note":"HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)","from":"hpv-negative-head-and-neck-cancer","refs":[]},{"group":"history","date":"2009","precision":"year","title":"MRC CR07 settles the timing of rectal radiotherapy","note":"Colorectal cancer. 1,350 patients; local recurrence 61 percent lower with short-course radiotherapy before surgery than with selective postoperative chemoradiotherapy, with no surv...","from":"colorectal","refs":["paper-sebag-montefiore-cr07-preoperative-radiotherapy-lancet-2009"]},{"group":"history","date":"2009","precision":"year","title":"MRD becomes the key risk factor","note":"Acute lymphoblastic leukaemia. AIEOP-BFM 2000 and UKALL 2003 show end-of-induction MRD outperforms every clinical factor; MRD-directed therapy adopted.","from":"all-leukemia","refs":["flow-cytometry-mrd","mrd-negative-cr"]},{"group":"history","date":"2009","precision":"year","title":"Multi-institutional registry of 405 patients","note":"Peritoneal mesothelioma. Yan and colleagues report median survival of 53 months after cytoreduction and HIPEC.","from":"peritoneal-mesothelioma","refs":[]},{"group":"history","date":"2009","precision":"year","title":"MYB-NFIB fusion identified as the defining genetic event","note":"Adenoid cystic carcinoma","from":"adenoid-cystic-carcinoma","refs":[]},{"group":"history","date":"2009","precision":"year","title":"MYB-NFIB fusion in adenoid cystic carcinoma (Persson, PNAS)","note":"Salivary gland cancers","from":"salivary-gland","refs":[]},{"group":"history","date":"2009","precision":"year","title":"NUT immunohistochemistry validated","note":"NUT carcinoma (midline carcinoma with NUTM1 rearrangement). Haack and colleagues: highly specific antibody enables diagnosis.","from":"nut-carcinoma","refs":[]},{"group":"history","date":"2009","precision":"year","title":"Ph-like (BCR-ABL1-like) ALL described by Dutch and US groups as a poor-prognosis subgroup","note":"Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL)","from":"all-ph-like","refs":[]},{"group":"history","date":"2009","precision":"year","title":"Pralatrexate and romidepsin approved","note":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma). First drugs specifically for relapsed PTCL.","from":"peripheral-t-cell-lymphoma","refs":["pralatrexate","romidepsin"]},{"group":"history","date":"2009","precision":"year","title":"PROMID: octreotide LAR slows midgut tumour growth","note":"Small intestinal neuroendocrine tumours","from":"small-intestinal-net","refs":["promid","octreotide-lanreotide"]},{"group":"history","date":"2009","precision":"year","title":"PROMID: octreotide slows tumour growth","note":"Neuroendocrine tumours","from":"neuroendocrine","refs":["promid"]},{"group":"history","date":"2009","precision":"year","title":"Single-arm phase 2: no local recurrences after breast conservation with radiotherapy for borderline and malignant tumours","note":"Phyllodes tumour of the breast","from":"phyllodes-tumour","refs":["imrt-igrt"]},{"group":"history","date":"2009","precision":"year","title":"SIOPEL-3: cisplatin alone suffices for standard risk (NEJM)","note":"Hepatoblastoma","from":"hepatoblastoma","refs":["cisplatin"]},{"group":"history","date":"2009","precision":"year","title":"Sunitinib shows activity in alveolar soft part sarcoma","note":"Alveolar soft part sarcoma","from":"alveolar-soft-part-sarcoma","refs":["sunitinib"]},{"group":"history","date":"2009","precision":"year","title":"The 1 mm margin rule in UK pathology reporting","note":"Pancreatic ductal adenocarcinoma. Tumour within 1 mm of a margin is R1 (Royal College of Pathologists); standardised protocols raised the reported R1 rate to 76 to 85 percent of he...","from":"pancreatic","refs":["r0-r1-margin-pancreatic","resection-margins"]},{"group":"history","date":"2009","precision":"year","title":"The two screening trials report on the same day and disagree","note":"Prostate cancer. ERSPC found a 20 percent reduction in prostate cancer mortality, at 1,410 men screened and 48 extra cancers treated per death prevented.","from":"prostate","refs":["erspc","plco-prostate","paper-schroder-erspc-screening-mortality-nejm-2009","paper-andriole-plco-prostate-screening-nejm-2009"]},{"group":"history","date":"2009","precision":"year","title":"Transoral robotic surgery FDA-cleared","note":"Head and neck squamous cell carcinoma","from":"head-and-neck","refs":["tors"]},{"group":"history","date":"2009","precision":"year","title":"Vismodegib phase 1 shows responses in advanced BCC (NEJM)","note":"Basal cell carcinoma","from":"basal-cell-carcinoma","refs":["vismodegib"]},{"group":"history","date":"2009","precision":"year","title":"Vismodegib phase 1: responses in advanced basal cell carcinoma (NEJM)","note":"Locally advanced and metastatic basal cell carcinoma","from":"locally-advanced-bcc","refs":["vismodegib"]},{"group":"journal","date":"2009","precision":"year","title":"Cancer epidemiology founded","note":"Elsevier","from":"cancer-epidemiology","refs":[]},{"group":"journal","date":"2009","precision":"year","title":"Cancers founded","note":"MDPI","from":"cancers-mdpi","refs":[]},{"group":"journal","date":"2009","precision":"year","title":"Oncotarget founded","note":"Impact Journals (Rapamycin Press LLC)","from":"oncotarget","refs":[]},{"group":"journal","date":"2009","precision":"year","title":"Science Translational Medicine founded","note":"American Association for the Advancement of Science","from":"science-translational-medicine","refs":[]},{"group":"law","date":"2009","precision":"year","title":"Family Smoking Prevention and Tobacco Control Act 2009","note":"United States, statute.","from":"tobacco-control-act","refs":[]},{"group":"law","date":"2009","precision":"year","title":"Supplementary protection certificate (EU)","note":"European Union, regulation.","from":"spc","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"A subtype of childhood acute lymphoblastic leukaemia with poor outcome: genome-wide classification study (BCR-ABL1-like ALL)","note":"Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. The Lancet Oncology.","from":"paper-den-boer-bcr-abl1-like-all-lancet-oncol-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"AALL0031: imatinib with intensive chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukaemia in children","note":"Schultz KR, Bowman WP, Aledo A, et al. Journal of Clinical Oncology.","from":"paper-aall0031-imatinib-ph-positive-all-schultz-jco-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Adaptive therapy","note":"Gatenby RA, Silva AS, Gillies RJ, et al. Cancer Research.","from":"paper-gatenby-cancer-res","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"AZA-001: azacitidine versus conventional care in higher-risk myelodysplastic syndromes","note":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. The Lancet Oncology.","from":"paper-aza-001-fenaux-lancet-oncol-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Cancer stem cells: mirage or reality?","note":"Gupta PB, Chaffer CL, Weinberg RA. Nature Medicine.","from":"paper-gupta-nat-med","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Cell cycle, CDKs and cancer: a changing paradigm","note":"Malumbres M, Barbacid M. Nature Reviews Cancer.","from":"paper-malumbres-nat-rev-cancer","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer (CRYSTAL)","note":"Van Cutsem E, Köhne CH, Hitre E, et al. New England Journal of Medicine.","from":"paper-van-cutsem-crystal-cetuximab-folfiri-nejm-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Cytoreductive surgery and HIPEC for malignant peritoneal mesothelioma: multi-institutional registry","note":"Yan TD, Deraco M, Baratti D, et al. Journal of Clinical Oncology.","from":"paper-yan-peritoneal-mesothelioma-crs-hipec-jco-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Deficient mismatch repair system in patients with sporadic advanced colorectal cancer","note":"Koopman M, Kortman GA, Mekenkamp L, et al. British Journal of Cancer.","from":"paper-koopman-deficient-mismatch-repair-advanced-colorectal-bjc-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukaemia","note":"Mullighan CG, Su X, Zhang J, et al. New England Journal of Medicine.","from":"paper-mullighan-ikzf1-nejm-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer","note":"Iacobuzio-Donahue CA, Fu B, Yachida S, et al. Journal of Clinical Oncology.","from":"paper-iacobuzio-donahue-dpc4-failure-pattern-autopsy-jco-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial","note":"Sjöström L, Gummesson A, Sjöström CD, et al. The Lancet Oncology.","from":"paper-sjostrom-lancet-oncol","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis","note":"Paavonen J, Naud P, Salmerón J, et al. The Lancet.","from":"paper-patricia-paavonen-lancet-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"ERSPC: screening and prostate cancer mortality in a randomised European study","note":"Schröder FH, Hugosson J, Roobol MJ, et al. New England Journal of Medicine.","from":"paper-schroder-erspc-screening-mortality-nejm-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis","note":"Fluge Ø, Gravdal K, Carlsen E, et al. British Journal of Cancer.","from":"paper-ezh2-colorectal-br-j-cancer-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","note":"Mok TS, Wu YL, Thongprasert S, et al. New England Journal of Medicine.","from":"paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","note":"Plotkin SR, Stemmer-Rachamimov AO, Barker FG, et al. New England Journal of Medicine.","from":"paper-plotkin-bevacizumab-nf2-nejm-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1","note":"Ligtenberg MJ, Kuiper RP, Chan TL, et al. Nature Genetics.","from":"paper-ligtenberg-epcam-deletion-msh2-silencing-nat-genet-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Homeopathic medicines for adverse effects of cancer treatments","note":"Kassab S, Cummings M, Berkovitz S, et al. The Cochrane database of systematic reviews.","from":"paper-kassab-cochrane-database-syst-rev","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"HPV screening for cervical cancer in rural India (Osmanabad)","note":"Sankaranarayanan R, Nene BM, Shastri SS, et al. New England Journal of Medicine.","from":"paper-sankaranarayanan-hpv-screening-nejm-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","note":"Olive KP, Jacobetz MA, Davidson CJ, et al. Science.","from":"paper-olive-hedgehog-stroma-gemcitabine-delivery-science-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Jemal 2009: Cancer statistics, 2009","note":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. CA: A Cancer Journal for Clinicians.","from":"paper-jemal-cancer-statistics-2009-cacancer-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Kalluri and Weinberg 2009: the basics of epithelial-mesenchymal transition","note":"Kalluri R, Weinberg RA. Journal of Clinical Investigation.","from":"paper-kalluri-weinberg-emt-basics-jci-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context","note":"Draisma G, Etzioni R, Tsodikov A, et al. JNCI: Journal of the National Cancer Institute.","from":"paper-draisma-lead-time-overdiagnosis-psa-jnci-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Management of lung nodules detected by volume CT scanning","note":"van Klaveren RJ, Oudkerk M, Prokop M, et al. New England Journal of Medicine.","from":"paper-van-klaveren-n-engl-j-med","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Matrix crosslinking forces tumor progression by enhancing integrin signaling","note":"Levental KR, Yu H, Kass L, et al. Cell.","from":"paper-levental-cell","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Mutation of FOXL2 in granulosa cell tumours of the ovary","note":"Shah SP, Köbel M, Senz J, et al. New England Journal of Medicine.","from":"paper-shah-foxl2-granulosa-nejm-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"No surgical innovation without evaluation: the IDEAL recommendations","note":"McCulloch P, Altman DG, Campbell WB, et al. The Lancet.","from":"paper-mcculloch-lancet","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Oncogenic EGFR signaling networks in glioma","note":"Huang PH, Xu AM, White FM. Science signaling.","from":"paper-egfr-glioblastoma-sci-signal-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Phase 2 study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater","note":"Overman MJ, Varadhachary GR, Kopetz S, et al. Journal of Clinical Oncology.","from":"paper-overman-capox-small-bowel-adenocarcinoma-jco-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"PLCO: mortality results from a randomised prostate cancer screening trial","note":"Andriole GL, Crawford ED, Grubb RL, et al. New England Journal of Medicine.","from":"paper-andriole-plco-prostate-screening-nejm-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016)","note":"Sebag-Montefiore D, Stephens RJ, Steele R, et al. The Lancet.","from":"paper-sebag-montefiore-cr07-preoperative-radiotherapy-lancet-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control","note":"Bonvalot S, Rivoire M, Castaing M, et al. Journal of Clinical Oncology.","from":"paper-bonvalot-retroperitoneal-sarcoma-compartmental-jco-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: result...","note":"Heng DY, Xie W, Regan MM, et al. Journal of Clinical Oncology.","from":"paper-heng-j-clin-oncol","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study","note":"Schmid P, Nagai Y, Agarwal R, et al. The Lancet.","from":"paper-schmid-placental-site-trophoblastic-tumour-outcomes-lancet-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"PROMID: octreotide LAR in the control of tumour growth in metastatic midgut neuroendocrine tumours","note":"Rinke A, Müller HH, Schade-Brittinger C, et al. Journal of Clinical Oncology.","from":"paper-promid-rinke-jco-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Prospective multi-institutional study of adjuvant radiotherapy after resection of borderline and malignant phyllodes tumours","note":"Barth RJ, Wells WA, Mitchell SE, et al. Annals of surgical oncology.","from":"paper-barth-phyllodes-adjuvant-radiotherapy-ann-surg-oncol-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening, 1986 to 2005","note":"Welch HG, Albertsen PC. JNCI: Journal of the National Cancer Institute.","from":"paper-welch-albertsen-psa-era-diagnosis-treatment-jnci-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Recurrent fusion of MYB and NFIB transcription factor genes in adenoid cystic carcinoma","note":"Persson M, Andrén Y, Mark J, et al. Proceedings of the National Academy of Sciences.","from":"paper-persson-myb-nfib-pnas-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Sato 2009: single Lgr5 stem cells build crypt-villus organoids","note":"Sato T, Vries RG, Snippert HJ, et al. Nature.","from":"paper-sato-lgr5-organoids-nature-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"SIOPEL-3: cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma","note":"Perilongo G, Maibach R, Shafford E, et al. New England Journal of Medicine.","from":"paper-siopel-3-cisplatin-vs-plado-standard-risk-hepatoblastoma-perilongo-nejm-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","note":"Parker JS, Mullins M, Cheang MC, et al. Journal of Clinical Oncology.","from":"paper-parker-j-clin-oncol","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"The cancer genome","note":"Stratton MR, Campbell PJ, Futreal PA. Nature.","from":"paper-stratton-nature","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"The International Neuroblastoma Risk Group (INRG) classification system","note":"Cohn SL, Pearson AD, London WB, et al. Journal of Clinical Oncology.","from":"paper-inrg-cohn-jco-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies","note":"Burger JA, Ghia P, Rosenwald A, et al. Blood.","from":"paper-jan-burger-blood-2009","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","note":"Vander Heiden MG, Cantley LC, Thompson CB. Science.","from":"paper-vander-heiden-science","refs":[]},{"group":"paper","date":"2009","precision":"year","title":"Weight lifting in women with breast-cancer-related lymphedema","note":"Schmitz KH, Ahmed RL, Troxel A, et al. New England Journal of Medicine.","from":"paper-schmitz-n-engl-j-med","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)","note":"Annals of Oncology","from":"marc-ychou","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from color...","note":"Annals of Oncology","from":"marc-ychou","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment","note":"Journal of Clinical Oncology","from":"robin-zon","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Aprepitant for the prevention of chemotherapy‐induced nausea and vomiting in adolescents","note":"Pediatric Blood & Cancer","from":"kent-stobart","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","note":"Cell","from":"irving-weissman","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Clinical characteristics and outcome of children with Burkitt lymphoma in Uganda according to HIV infection","note":"Pediatric Blood & Cancer","from":"jackson-orem","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhi...","note":"Clin Cancer Res","from":"oddbjorn-straume","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer","note":"Nature Medicine","from":"william-nelson","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Current evidence on the burden of head and neck cancers in Nigeria","note":"Head & Neck Oncology","from":"wasiu-lanre-adeyemo","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","note":"Science","from":"charles-sawyers","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Distinctive chromatin in human sperm packages genes for embryo development","note":"Nature","from":"bradley-cairns","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data","note":"BMJ","from":"peter-sasieni","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year...","note":"Lancet Oncology","from":"monika-hegi","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-co...","note":"Lancet Oncology","from":"ann-lii-cheng","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, ph...","note":"Lancet Oncology","from":"pierre-fenaux","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","note":"Clinical Cancer Research","from":"jedd-wolchok","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"High incidence of hearing loss in long‐term survivors of multisystem Langerhans cell histiocytosis","note":"Pediatric Blood & Cancer","from":"vasanta-nanduri","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma (IELSG20)","note":"Lancet","from":"andres-ferreri","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Histological heterogeneity of Ewing’s sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support","note":"Virchows Archiv","from":"antonio-llombart-bosch","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"HPV screening for cervical cancer in rural India","note":"New England Journal of Medicine","from":"sankaranarayanan-rengaswamy","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis","note":"Lancet","from":"victor-hugo-borja-aburto","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice","note":"PLoS Medicine","from":"gianvito-martino","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo","note":"Nature Immunology","from":"jeffrey-bluestone","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Integrating a 1.5 T MRI scanner with a 6 MV accelerator: proof of concept","note":"Physics in Medicine and Biology","from":"bas-raaymakers","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor–Positive Breast Cancer","note":"Journal of Clinical Oncology","from":"frederique-penault-llorca","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children'...","note":"Journal of Clinical Oncology","from":"katherine-matthay","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt","note":"Nature Protocols","from":"ewan-birney","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients","note":"Radiotherapy and Oncology","from":"jean-bourhis","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","note":"Blood","from":"ola-landgren","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2)","note":"Radiotherapy and Oncology","from":"vincenzo-valentini","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"One Step Forward Toward Identification of the Genetic Signature of Glioblastomas","note":"JAMA","from":"boris-pasche","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis","note":"Proceedings of the National Academy of Sciences","from":"yosef-yarden","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study","note":"Journal of Clinical Oncology","from":"evanthia-galanis","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","note":"Blood","from":"john-dipersio","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomise...","note":"Lancet","from":"david-sebag-montefiore","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Rethinking screening for breast cancer and prostate cancer","note":"JAMA","from":"laura-esserman","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multi...","note":"Cancer","from":"andreas-du-bois","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Sex-associated differences in non-small cell lung cancer in the new era: Is gender an independent prognostic factor?","note":"Lung Cancer","from":"nei-min-chu","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Supervised risk predictor of breast cancer based on intrinsic subtypes (PAM50)","note":"JCO","from":"charles-perou","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Surgeon recommendations and receipt of mastectomy for treatment of breast cancer","note":"JAMA","from":"monica-morrow","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"The biology of chromatin remodeling complexes","note":"Annual Review of Biochemistry","from":"bradley-cairns","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung c...","note":"Journal of Thoracic Oncology","from":"valerie-rusch","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report","note":"Journal of Clinical Oncology","from":"susan-cohn","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"The LKB1–AMPK pathway: metabolism and growth control in tumour suppression","note":"Nature Reviews Cancer","from":"reuben-shaw","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"The R.E.N.A.L. Nephrometry Score: A Comprehensive Standardized System for Quantitating Renal Tumor Size, Location and Depth","note":"Journal of Urology","from":"robert-uzzo","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Tratamiento combinado con antagonistas del calcio e inhibidores de la enzima de conversión de angiotensina (IECA) como terapia inicial preferible a diuréticos e...","note":"FMC - Formación Médica Continuada en Atención Primaria","from":"alvaro-bonet-pla","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation (Total Therapy XV)","note":"NEJM","from":"ching-hon-pui","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Tumor Suppression by LKB1: SIK-ness Prevents Metastasis","note":"Science Signaling","from":"reuben-shaw","refs":[]},{"group":"person-paper","date":"2009","precision":"year","title":"Vasa Vasorum and Plaque Neovascularization on Contrast-Enhanced Carotid Ultrasound Imaging Correlates With Cardiovascular Disease and Past Cardiovascular Events","note":"Stroke","from":"daniel-staub","refs":[]},{"group":"technology","date":"2009","precision":"year","title":"Adaptive therapy (evolution-based dosing)","note":"First use in humans or first approval, as the technology record states it.","from":"adaptive-therapy-dynamics","refs":[]},{"group":"technology","date":"2009","precision":"year","title":"PI3K, AKT and mTOR inhibitors","note":"First use in humans or first approval, as the technology record states it.","from":"pi3k-akt-mtor-inhibitors","refs":[]},{"group":"technology","date":"2009","precision":"year","title":"Radiogenomics: predicting radiation sensitivity from genes","note":"First use in humans or first approval, as the technology record states it.","from":"radiogenomics","refs":[]},{"group":"technology","date":"2009","precision":"year","title":"Transoral robotic surgery (TORS)","note":"First use in humans or first approval, as the technology record states it.","from":"tors","refs":[]},{"group":"trial","date":"2009","precision":"year","title":"A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma reported","from":"nct00229203","refs":["multiple-myeloma","plitidepsin"]},{"group":"trial","date":"2009","precision":"year","title":"AZA-001 reported","note":"Azacitidine improved overall survival over conventional care regimens in higher-risk myelodysplastic syndromes.","from":"aza-001","refs":["mds-higher-risk","mds","azacitidine"]},{"group":"trial","date":"2009","precision":"year","title":"CRYSTAL & FIRE-3 reported","note":"CRYSTAL KRAS-WT OS 23.5 vs 20.0 months; FIRE-3 OS 28.7 vs 25.0 months.","from":"crystal-fire3","refs":["colorectal","cetuximab","bevacizumab","folfiri"]},{"group":"trial","date":"2009","precision":"year","title":"EORTC 22961 reported","note":"Five-year overall mortality 19.0 percent with 6 months of androgen suppression against 15.2 percent with 3 years; hazard ratio 1.42, non-inferiority not shown (p=0.65).","from":"eortc-22961","refs":["prostate","prostate-high-risk"]},{"group":"trial","date":"2009","precision":"year","title":"MRC CR07 reported","note":"Local recurrence at three years 4.4 percent with short-course preoperative radiotherapy against 10.6 percent with selective postoperative chemoradiotherapy (hazard ratio 0.39, 0.27...","from":"cr07","refs":["colorectal","rectal-cancer"]},{"group":"trial","date":"2009","precision":"year","title":"Osmanabad cervical screening trial (HPV testing vs cytology vs VIA) reported","note":"Cervical cancer deaths HR 0.52 with one round of HPV testing; no significant effect of cytology or VIA.","from":"osmanabad-hpv-screening","refs":["cervical"]},{"group":"trial","date":"2009","precision":"year","title":"PATRICIA reported","note":"Vaccine efficacy against CIN2+ associated with HPV-16/18 92.9% (96.1% CI 79.9 to 98.3) in the according-to-protocol efficacy cohort; 98.1% with HPV-type causality assigned.","from":"patricia","refs":["cervical","hpv-bivalent-vaccine"]},{"group":"trial","date":"2009","precision":"year","title":"PETACC-3 reported","note":"Five-year disease-free survival 56.7 against 54.3 percent (p=0.106); no overall survival gain.","from":"petacc-3","refs":["colorectal","colon-cancer","irinotecan","fluorouracil"]},{"group":"trial","date":"2009","precision":"year","title":"PLCO, prostate component (Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial) reported","note":"Prostate cancer death rate 2.0 against 1.7 per 10,000 person-years, rate ratio 1.13 (95 percent confidence interval 0.75 to 1.70), not significant; control-group PSA testing rose f...","from":"plco-prostate","refs":["prostate"]},{"group":"trial","date":"2009","precision":"year","title":"PROMID reported","note":"TTP 14.3 vs 6.0 months, HR 0.34.","from":"promid","refs":["neuroendocrine","small-intestinal-net","octreotide-lanreotide"]},{"group":"trial","date":"2009","precision":"year","title":"SIOPEL-3 reported","note":"Complete resection 95 percent with cisplatin alone against 93 percent with cisplatin plus doxorubicin; three-year overall survival 95 against 93 percent; grade 3 or 4 toxicity 20.6...","from":"siopel-3","refs":["hepatoblastoma","childhood-cancers","cisplatin","doxorubicin"]},{"group":"trial","date":"2009","precision":"year","title":"SPCG-7/SFUO-3 reported","note":"Ten-year prostate cancer mortality 11.9 percent with hormones plus radiotherapy against 23.9 percent with hormones alone (relative risk 0.44, 95 percent confidence interval 0.30 to...","from":"spcg-7","refs":["prostate","prostate-high-risk","flutamide"]},{"group":"trial","date":"2009","precision":"year","title":"SWOG 8794 reported","note":"Metastasis-free survival hazard ratio 0.71 (95 percent confidence interval 0.54 to 0.94, p=0.016) and overall survival hazard ratio 0.72 (0.55 to 0.96, p=0.023) with adjuvant radio...","from":"swog-8794","refs":["prostate","prostate-high-risk","prostate-bcr"]}]},"route":"/years/2009/","neighbours":{"year":[{"id":"2008","kind":"year","name":"2008 in oncology","route":"/years/2008/"},{"id":"2010","kind":"year","name":"2010 in oncology","route":"/years/2010/"}]}}